Top Biotech Stock Movers: AVIR, CRBP, ATOS, NKTX
1:54 pm Friday, May 14th, 2021
Here are the following top 4 biotech stocks gainers in Friday’s trading session:
Atea Pharmaceuticals Inc (NASDAQ:AVIR) is the biggest gainer in the biotech space on Friday. The stock is now up by 24% at $23.83. The stock has fallen over 75% over the past 2 months. Collaboration revenue for the first quarter ended March 31, 2021 in the amount of $66.0 million was derived from the license agreement Atea entered into with F. Hoffmann-La Roche Ltd. and Genentech, Inc. in October 2020.
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) gained 22% to $1.69. Last month, the company announced that the last participant was enrolled in a Phase 2 study of lenabasum for the treatment of systemic lupus erythematosus (SLE).
Atossa Therapeutics Inc (NASDAQ:ATOS) stock has surged 18% to $2.79. In April, the company announced that an ovarian cancer patient has begun treatment with Atossa’s proprietary oral Endoxifen.
The FDA previously issued a “Safe to Proceed” letter under their expanded access pathway, permitting the use of Atossa’s oral Endoxifen in this patient. The patient is being treated at the University of Washington Medical Center by Dr. Barbara Goff, Surgeon-in-Chief.
Nkarta Inc (NASDAQ:NKTX) jumped 17% to $28.03 after the company reported first-quarter results and business progress. As of March 31, 2021, Nkarta had cash, cash equivalents, restricted cash, and short-term investments of $299.7 million. Net loss was $19.4 million, or $0.59 per basic and diluted share, for the first quarter of 2021.
